Search
Cephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971. … [A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide.
Synonyms: (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidInternational brands: L-KeflexParoxetine
go.drugbank.com/drugs/DB00715ApprovedInvestigational[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. … Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.
Products: PAROXETINA EG, PAROXETINA EG STADALorazepam
go.drugbank.com/drugs/DB00186ApprovedInvestigationalLorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. … [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977.
Products: LORAZEPAM EGPerindopril
go.drugbank.com/drugs/DB00790ApprovedInvestigationalIt is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. … ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS).
Mixtures: Arcosyl Plus Ld, Coversyl Plus LdCategories: Agents Acting on the Renin-Angiotensin SystemEzetimibe
go.drugbank.com/drugs/DB00973ApprovedInvestigational[A33313] In genetically NPC1L1-deficient mice, a 70% reduction in intestinal cholesterol absorption was seen, and these mice were insensitive to ezetimibe treatment - it was determined based on these findings … [A15202] Ezetimibe is used as an adjunctive therapy to a healthy diet to lower cholesterol levels in primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous
Mixtures: TIAZOMET ® A 40/10 TABLETAS, EZETIMIBE E SIMVASTATINA EGProducts: EZETIMIBE EG, EZETIMIB AL 10MGDexibuprofen
go.drugbank.com/drugs/DB09213ApprovedWithdrawnDexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. … Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259].
Products: Eu-Med 200 mg SchmerztablettenLovastatin
go.drugbank.com/drugs/DB00227ApprovedInvestigationalwere found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while lovastatin has been found to have an average decrease in LDL-C of 25-40%. … leading cause of death in high-income countries and a major cause of morbidity around the world.
Products: LOVASTATINA EG, LOVASTATIN AL 20MG TABLValaciclovir
go.drugbank.com/drugs/DB00577ApprovedInvestigationalIt was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline [L5671]. Valacyclovir is the L-valine ester of aciclovir. … It is a member of the purine (guanine) nucleoside analog drug class [F3949]. This class of drugs forms an important part of hepatitis, HIV, and cytomegalovirus drug regimens [A175900].
Synonyms: L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine, L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl esterProducts: VALACICLOVIR EGAcorus calamus root
go.drugbank.com/drugs/DB14292InvestigationalAcorus calamus root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Products: derma MOBALNA EP 90 Hair Again TonerAzacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigationalAzacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]
Products: AZACITIDINA EG